MRC1 and colorectal carcinoma: Indeed, a health economics analysis recently published by Erten et al. [56] concluded that universal testing of CRC patients for LS based on sequencing alone will become more cost effective than the two-step test when the cost of MMR gene sequencing drops to or below $609 USD, echoing a similar finding by Gould-Suarez et al. [56, 57].